Active — Not RecruitingNot Applicable

Tyrosine Allergoid Paediatric and Adult Study

Germany320 participantsStarted 2020-11-06

Plain-language summary

The primary objective of this 5-year study is to demonstrate non-inferiority of children compared to adults by exploring long-term effectiveness after treatment with TA Bäume (trees) and TA Gräser (grass) following a perennial posology.

Who can participate

Age range5 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients from 5 years of age who are treated with TA Gräser top or TA Bäume top due to rhinitis, conjunctivitis and/or mild to moderate bronchial asthma, which are caused by an IgE-mediated allergy to grass and rye pollen or birch, alder and hazel pollen according to the respective SmPC. * Patients will only be included in this study after the decision on the treatment has been made. Exclusion Criteria: * History of allergen-specific immunotherapy (SIT) for trees or grass within the last 5 years * If it´s intended to treat the patient with only a preseasonal therapy * A patient should also not be included in the presence of any of the conditions listed in the respective SmPC

What they're measuring

change in the combined symptom medication score (CSMS)

Timeframe: once a year for 5 years

Trial details

NCT IDNCT05186025

SponsorAllergy Therapeutics

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2026-06

View on ClinicalTrials.gov More Allergic Rhinitis Due to Pollen trials